SLÁVIK, Marek, Petr BURKOŇ, Tomáš KAZDA, Marie BUDÍKOVÁ, M. SLAVIKOVA, E. DVORAKOVA, Petr POSPÍŠIL, J. GOMBOSOVA, P. NAVRATILOVA a Pavel ŠLAMPA. Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience. Neoplasma. Bratislava: Slovenská akademie vied, roč. 61, č. 6, s. 739-746. ISSN 0028-2685. doi:10.4149/neo_2014_090. 2014.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience
Autoři SLÁVIK, Marek (703 Slovensko, domácí), Petr BURKOŇ (203 Česká republika, domácí), Tomáš KAZDA (203 Česká republika, domácí), Marie BUDÍKOVÁ (203 Česká republika, domácí), M. SLAVIKOVA (203 Česká republika), E. DVORAKOVA (203 Česká republika), Petr POSPÍŠIL (203 Česká republika, domácí), J. GOMBOSOVA (203 Česká republika), P. NAVRATILOVA (203 Česká republika) a Pavel ŠLAMPA (203 Česká republika, garant, domácí).
Vydání Neoplasma, Bratislava, Slovenská akademie vied, 2014, 0028-2685.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Slovensko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 1.865
Kód RIV RIV/00216224:14110/14:00077947
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.4149/neo_2014_090
UT WoS 000345950900013
Klíčová slova anglicky adjuvant chemoradiation; gastric cancer; early toxicity; late toxicity; survival outcomes
Štítky EL OK, podil
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 3. 2. 2015 12:30.
Anotace
Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan-Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.
Návaznosti
CZ.1.07/2.4.00/17.0100, interní kód MUNázev: A-Math-Net Síť pro transfer znalostí v aplikované matematice
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, A-Math-Net Síť pro transfer znalostí v aplikované matematice, 2.4 Partnerství a sítě
VytisknoutZobrazeno: 20. 4. 2024 05:44